GPCRs-Targeted Drug Discovery Summit Leaderboard
  • Monday, May 4, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Obesity & Weight Loss Drug Development Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 65

Author

Pharma Journalist 8769 posts 0 comments

Capsida to Begin Phase 1/2 Trial of CAP-003 in Q3

Jun 13, 2025
Capsida Biotherapeutics announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-003, its potential best-in-class…
Read More...

Novo Nordisk Advances Amycretin for Weight Loss to Phase 3 Trials

Jun 13, 2025
Novo Nordisk announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance…
Read More...

BioNTech to Acquire CureVac in Strategic Public Exchange Deal

Jun 13, 2025
 BioNTech SE and CureVac N.V. announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a…
Read More...

FDA Approves MAVYRET as First Treatment for Acute Hepatitis C

Jun 13, 2025
AbbVie announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA)…
Read More...

Enhancing Collaboration: Networking Opportunities at the Summit

Jun 10, 2025
One of the most valuable aspects of the Microbiome Movement Summit is its emphasis on meaningful connections. With over 8 hours of structured networking built into the agenda, attendees…
Read More...

FDA Approves Merck’s ENFLONSIA for RSV Prevention in Infants

Jun 10, 2025
Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of…
Read More...

YolTech Therapeutics Gets FDA Green Light for Gene-Editing Therapy YOLT-101 for HeFH

Jun 10, 2025
YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, announced that the U.S. Food and Drug Administration (FDA) has cleared the…
Read More...

EU Approves Fixed-Duration Calquence Regimens for 1st-Line CLL

Jun 10, 2025
A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for the…
Read More...

Aytu BioPharma Secures Exclusive US Rights for Novel Antidepressant EXXUA

Jun 10, 2025
Aytu BioPharma, Inc. announced the signing of an exclusive agreement to commercialize EXXUA (gepirone) extended-release tablets ("EXXUA") in the United States. Gepirone is a new…
Read More...

Alnylam’s AMVUTTRA Wins EU Approval for ATTR Amyloidosis with Cardiomyopathy

Jun 10, 2025
Alnylam Pharmaceuticals, Inc. announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients…
Read More...
Prev Next
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
GPCRs-Targeted Drug Discovery Summit
5th World ADC Summit South Korea
Extrahepatic Lipid-Based Nanoparticles Delivery Summit
World TPD & Induced Proximity Summit South Korea
Measuring Patient Engagement Summit
Investigative & Preclinical Toxicology Summit 2026
LEAP HR: Life Sciences West
Oligonucleotides for CNS Summit
R&D Procurement & Sourcing in Pharma Summit
In Vivo Cell Engineering & Gene Editing Summit
PFS & Injectable Drug Delivery West Coast
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
World Bispecific & T-Cell Engager Summit South Korea
TCR-Based Therapies Summit
PFS & Injectable Drug Devices East Coast
5th ADC Analytical Development Summit
Nasal Formulation & Delivery Summit
Peptide-Based Therapeutics Summit 2026
ALS Drug Development Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Gilead Completes $7.8 Billion Arcellx Acquisition Deal
  • EU Approves Rhapsido for Chronic Hives Treatment
  • Lilly to Acquire Ajax in $2.3 Billion Deal
  • Saphnelo Pen Approval Expands Lupus Treatment Access
  • BioMarin Completes $4.8 Billion Amicus Acquisition

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

Turning Biophysical Data into Confident Drug Discovery…

Targeted LNP Delivery Beyond the Liver: The Challenges…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.